CRISPR Therapeutics AG (NASDAQ: CRSP) started the day on Wednesday, with a price increase of 3.10% at $50.84, before settling in for the price of $49.31 at the close. Taking a more long-term approach, CRSP posted a 52-week range of $43.42-$91.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 33402.13%. Meanwhile, its Annual Earning per share during the time was 10.83%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -165.41%. This publicly-traded company’s shares outstanding now amounts to $85.35 million, simultaneously with a float of $81.67 million. The organization now has a market capitalization sitting at $4.47 billion. At the time of writing, stock’s 50-day Moving Average stood at $48.05, while the 200-day Moving Average is $56.70.
CRISPR Therapeutics AG (CRSP) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. CRISPR Therapeutics AG’s current insider ownership accounts for 4.31%, in contrast to 67.65% institutional ownership. According to the most recent insider trade that took place on Nov 11 ’24, this organization’s Chief Executive Officer sold 30,000 shares at the rate of 55.62, making the entire transaction reach 1,668,678 in total value, affecting insider ownership by 196,540. Preceding that transaction, on Oct 14 ’24, Company’s General Counsel and Secretary sold 1,089 for 46.28, making the whole transaction’s value amount to 50,399. This particular insider is now the holder of 62,597 in total.
CRISPR Therapeutics AG (CRSP) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.38 per share during the current fiscal year.
CRISPR Therapeutics AG’s EPS decrease for this current 12-month fiscal period is -165.41% and is forecasted to reach -5.01 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -3.70% through the next 5 years, which can be compared against the 10.83% growth it accomplished over the previous five years trading on the market.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
Let’s observe the current performance indicators for CRISPR Therapeutics AG (CRSP). It’s Quick Ratio in the last reported quarter now stands at 21.64. The Stock has managed to achieve an average true range (ATR) of 2.35. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 22.06.
In the same vein, CRSP’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.82, a figure that is expected to reach -1.22 in the next quarter, and analysts are predicting that it will be -5.01 at the market close of one year from today.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
If we take a close look at the recent performances of CRISPR Therapeutics AG (NASDAQ: CRSP), its last 5-days Average volume was 1.61 million that shows progress from its year to date volume of 1.49 million. During the previous 9 days, stock’s Stochastic %D was recorded 72.50% While, its Average True Range was 2.38.
Raw Stochastic average of CRISPR Therapeutics AG (CRSP) in the period of the previous 100 days is set at 36.62%, which indicates a major fall in contrast to 39.31% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 59.47% that was higher than 49.04% volatility it exhibited in the past 100-days period.
